Table 1

Severity of symptoms and medications used during the month prior to assessment at baseline and 36 months

Variable

Baseline

All patients

N = 987

Baseline

Followed up

N = 806

36 months

Followed up

N = 806


Pain NRS in most painful knee, mean ± SD

5.5 ± 2.4

5.4 ± 2.4

4.8 ± 2.8

Prescription analgesic used at any time

30.1%

29.4%

24.2%a

Prescription or OTC analgesic used frequentlyb

47.8%

47.9%

42.9%

Nutraceuticals used frequentlyb

41.3%

43.4%

36.0%a

Number of medications          Analgesics

0:

52.2%

52.1%

57.1%

used frequentlyb

1:

36.0%

37.6%

33.3%

2:

9.9%

8.8%

7.8%

≥3:

1.9%

1.5%

1.8%

                                      Nutraceuticals

0:

58.7%

56.6%

64.0%a

1:

4.1%

4.2%

4.1% a

2:

30.1%

31.5%

22.8% a

≥3:

6.8%

7.7%

9.1% a

Patient-reported medication use:

Acetaminophenb

13.5%

12.5%

14.4%

Prescription NSAIDsb

8.2%

8.1%

9.3%

OTC NSAIDsb

26.8%

26.7%

21.3%a

Coxibsb

10.2%

9.8%

4.7%a

Opioidsb

3.3%

3.0%

5.0%

Chondroitin and/or Glucosamineb

40.7%

42.9%

35.4%a

Other nutraceuticalb

8.6%

8.8%

10.2%

Intra-articular steroid injectionc

4.2%

4.3%

7.3%

Intra-articular hyaluronan injectionc

2.0%

1.7%

3.3%

Medications brought into visit or identifiedd:

N = 820

N = 690

N = 690

Proton pump inhibitor/H2 antagonist

11.2%

9.4%

21.4%

NSAID

7.7%

6.6%

13.9%

Coxib

11.6%

9.3%

5.2%

NSAID + PPI (% of NSAID users)

7.2% (6/83)

9.4% (5/53)

26.0% (25/96)

Coxib + PPI (% of coxib users)

34.9% (29/83)

30.7% (23/75)

41.7% (15/36)


astatistically significant change from baseline; bfor more than ½ days in the previous month; cin the previous 6 months; din the previous month, brought in or identified in list of medication; Coxibs, COX-II inhibitors; KL, Kellgren-Lawrence; OTC, over the counter; NSAID, non-steroidal anti-inflammatory drug; NRS, numerical rating scale; PPI, proton pump inhibitor; SD, standard deviation.

Kingsbury et al. Arthritis Research & Therapy 2013 15:R106   doi:10.1186/ar4286

Open Data